An oral medicine for hair loss successfully spurred hair growth in a late-stage trial, startup Veradermics announced Monday. Veradermics assessed the pill in two ways: by how many hairs grew within a square centimeter of the scalp, on average, and by how satisfied participants were with the results.
Over the course of six months, men who took the drug, known as VDPHL01, either once or twice daily had between 30 and 33 more hairs per square centimeter of scalp. Men in the placebo group grew approximately seven additional hairs.
Between 79% and 86% of men taking VDPHL01 said they saw improvement, along with between 72% and 84% of the clinical trial investigators — results that pleased Reid Waldman, a dermatologist turned Veradermics’ chief executive. Continue to STAT+ to read the full story...
An investigational oral agent for androgenetic hair loss, VDPHL01, was evaluated in a late-stage randomized trial assessing hair regrowth and participant/investigator perception of improvement.
The trial measured change in hair count per square centimeter of scalp and captured satisfaction assessments from participants and clinical investigators.
Treatment durations reported were six months.
Dosing arms included once-daily and twice-daily administration; a placebo arm was used as comparator.
The published summary specifies treated men as the analyzed population.
Exact sample size, randomization details, inclusion/exclusion criteria, and baseline characteristics were not reported in the source.
After six months, men receiving VDPHL01 (either dosing regimen) had mean increases of 30–33 hairs/cm2.
Placebo recipients increased by about seven hairs/cm2.
Reported proportions of perceived improvement ranged from 79%–86% among treated men and 72%–84% among investigators.
Full trial methodology, statistical analyses, safety data, and longer-term outcomes were not provided in the source.